What is William Blair's Estimate for VIGL Q1 Earnings?

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Stock analysts at William Blair issued their Q1 2026 earnings per share estimates for Vigil Neuroscience in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst S. Schram expects that the company will post earnings per share of $0.49 for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share. William Blair also issued estimates for Vigil Neuroscience's Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($2.12) EPS.

Several other equities analysts have also recently weighed in on the company. Wedbush cut their price objective on Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating on the stock in a report on Friday, March 14th. HC Wainwright cut their price objective on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Friday, March 14th. Guggenheim reiterated a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, JMP Securities reiterated a "market outperform" rating and set a $22.00 price objective on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $16.25.

Remove Ads

Vigil Neuroscience Stock Performance

VIGL traded down $0.10 during midday trading on Monday, reaching $1.83. 112,745 shares of the company were exchanged, compared to its average volume of 468,773. Vigil Neuroscience has a one year low of $1.49 and a one year high of $6.06. The stock has a market capitalization of $74.81 million, a P/E ratio of -0.89 and a beta of 1.82. The stock's 50-day simple moving average is $2.35 and its 200 day simple moving average is $2.75.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08).

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VIGL. Woodline Partners LP grew its holdings in Vigil Neuroscience by 239.1% in the 4th quarter. Woodline Partners LP now owns 488,756 shares of the company's stock valued at $831,000 after buying an additional 344,614 shares in the last quarter. Blair William & Co. IL acquired a new position in Vigil Neuroscience in the 4th quarter valued at $551,000. Renaissance Technologies LLC grew its holdings in Vigil Neuroscience by 698.5% in the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company's stock valued at $624,000 after buying an additional 321,300 shares in the last quarter. abrdn plc increased its position in shares of Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company's stock worth $898,000 after purchasing an additional 293,461 shares during the period. Finally, Trustees of Columbia University in the City of New York bought a new position in shares of Vigil Neuroscience in the fourth quarter worth $328,000. 83.64% of the stock is owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.